Ibiglustat

Research use only, not for human use.

An orally active, selective and potent Glucosylceramide synthase (GCS) inhibitor with central nervous system (CNS) access.

An orally active, selective and potent Glucosylceramide synthase (GCS) inhibitor with central nervous system (CNS) access; exhibits significantly lower tissue levels of GL-3 and lyso-GL-3 and a delayed progression of a thermal nociceptive response in administered Fabry mice; shows favorable pharmacological properties and safety profile.Other Indication Phase 2 Clinical(In Vitro):Ibiglustat (SAR402671) (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.

——

——

Venglustat | Genz-682452 | GZ452

Others

Other Targets

glucosylceramide synthase

Other Indications

Other Disease

1401090-53-6

389.49

C20H24FN3O2S

>98% (HPLC)

DMSO: 10 mM （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C

(3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)- 1,3-thiazol-4-yl]propan-2-yl}carbamate

(-20℃)

With Ice Pack

≥ 2 years